Samuel T. Wilkinson, MD
Advertisement
Articles by Samuel T. Wilkinson, MD
Experts present the results of a retrospective analysis of patients who received IV ketamine for TRD over a timeframe of up to 2 years.
What is the efficacy of ECT for the treatment of dementia?
Samuel T. Wilkinson, MD, discusses the risks and benefits, as well as the challenges of clinical implementation of esketamine, for treatment-resistant depression.
Advertisement
Latest Updated Articles
Electroconvulsive Therapy for the Treatment of Dementia SymptomsOctober 14th 2024
What Is the Deal With Esketamine?April 6th 2020
Advertisement
Advertisement
Trending on Psychiatric Times
1
New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose
2
The Postmodern Worldview and Contemporary Psychiatry
3
New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
4
DT120 (Lysergide) ODT Receives Breakthrough Therapy Designation for Treatment of MDD
5